Overall, as the majority of our HNSCC cell lines demonstrated high EGFR, HER2, and HER3 expression under normal and reduced oxygen conditions, these intrinsically cetuximab‐resistant and acquired cetuximab‐resistant HNSCC cell lines are valid target candidates for afatinib treatment. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.